Table 1.
Changes in Viability, Myocardial Fiber Architecture, and Cardiac Function
| CDCEXO | Placebo | |
|---|---|---|
| SS | ||
| Pre (%) | 17 (3) | 19 (2) |
| Post (%) | 13 (2)∗ | 18 (3) |
| Δ (%) | −27 (9)† | −4 (13) |
| |HAT| | ||
| Pre (°/%TD) | 1.00 (0.06) | 1.02 (0.07) |
| Post (°/%TD) | 1.02 (0.06)∗ | 0.91 (0.09) |
| Δ (%) | −2 (5) | −14 (4)† |
| LVEF | ||
| Pre (%) | 41 (3) | 40 (6) |
| Post (%) | 42 (5)∗ | 35 (8) |
| Δ (%) | −2 (7) | −17 (6)† |
| LVEDV | ||
| Pre (ml) | 76 (12) | 77 (16) |
| Post (ml) | 84 (7)† | 93 (18) |
| Δ (%) | 16 (10)† | 21 (10)† |
| LVESV | ||
| Pre (ml) | 45 (14) | 46 (18) |
| Post (ml) | 49 (4)∗ | 63 (23) |
| Δ (%) | 16 (14)† | 32 (15)† |
| SV | ||
| Pre (ml) | 29 (2) | 31 (2) |
| Post (ml) | 34 (3)∗ | 32 (6) |
| Δ (%) | 9 (5)† | 3 (5) |
Values are median (interquartile range).
Δ = normalized change (post – pre)/pre; CDCEXO = exosomes of cardiosphere-derived cells; |HAT| = absolute helix angle transmurality; IQR = interquartile range; LVEDV = left ventricular end-diastolic volume; LVEF = left ventricular ejection fraction; LVESV = left ventricular end-systolic volume; post = post-treatment; pre = pre-treatment; SS = scar size; SV = stroke volume; TD = transmural depth.
CDCEXO vs placebo, p < 0.05.
pre vs post, p < 0.05. Significant (p = 0.03) reduction in scar size with preserved ejection fraction and helix angle transmurality were observed in the CDCEXO group. Significant (p = 0.03 and p = 0.03, respectively) reduction in EF and helix angle transmurality with no change in scar size were observed in the placebo group.